Biocept (BIOC) Delnica Cena
Biocept Cena
Revenue has compounded at 150,7% per year over the past 11 years to 25,86 Mio. USD. Biocept's net margin stands at −124,1%, up from −756,0% several years earlier. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Cena delnice Biocept
Podrobnosti
Cena delnice
ⓘKako prebrati ta grafikon
Ta grafikon sledi zgodovinski ceni delnice Biocept skozi čas. Lahko preklapljate med dnevnimi, tedenskimi in mesečnimi prikazi ter izberete prilagojene časovne intervale – od enega dne do celotne razpoložljive zgodovine. Uporabite stikalo za prikaz sprememb cen v absolutnih valutnih pogojih ali kot odstotna sprememba glede na začetni datum.
Skupni prinos v primerjavi s cenovnim prinosom
Stikalo "Skupni prinos" vključuje reinvestirane dividende na vrh čistega gibanja cene. To je kritično, ker lahko dividende predstavljajo pomemben del dolgoročnih prinosov. Zgodovinsko so dividende predstavljale približno 40 % skupnega prihoda S&P 500. Vedno primerjajte skupni prinos pri vrednotenju prave zmogljivosti delnice glede na referenčni indeks.
Podatki o cenah v realnem času
Pri pregledu časovnega okvira enega dne grafikon prikazuje gibanja cen v realnem času intraday. To je koristno za opazovanje, kako se delnica Biocept odziva na odpiranje trga, objave dobičkov ali novice v realnem času med trgovalno sejo.
Kaj iskati
Poglejte si dolgoročne trende (trajnostna gibanja navzgor ali navzdol v mesecih in letih), podporne in odporne ravni (cenovne cone, kjer se delnica ponavljajoče odbija ali spreminja smer) in volatilnost (kako se cena nihanja dan za dnem). Primerjava grafikona cene Biocept z indeksom trga, kot je S&P 500, lahko razkrije, ali delnica presega ali zaostaja za širšim trgom.
| Datum | Biocept Cena |
|---|
Biocept Prihodek, EBIT, Neto dobiček
3 leta
5 let
10 let
25 let
Največ
Details
Biocept Izkaz poslovnega izida, Bilanca stanja, Izkaz denarnih tokov
| PRIHODKIMio. USD |
|---|
| RAST PRIHODKOV% |
| BRUTTOMARJA% |
| BRUTO DOHODEKMio. USD |
| EBITMio. USD |
| EBIT MARJA% |
| ČISTI DOHODEKMio. USD |
| RAST ČISTEGA DOBIČKA% |
| DELNICEMio. |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | 3,00 | 5,00 | 3,00 | 5,00 | 27,00 | 61,00 | 25,00 | 2,00 | 6,00 | 21,00 | 21,00 |
| – | – | – | – | – | – | 66,67 | −40,00 | 66,67 | 440,00 | 125,93 | −59,02 | −92,00 | 200,00 | 250,00 | – |
| – | – | – | – | – | −100,00 | −80,00 | −200,00 | −100,00 | 22,22 | 37,70 | −8,00 | −8,00 | −8,00 | −8,00 | −8,00 |
| −2,00 | −1,00 | −2,00 | −2,00 | −3,00 | −3,00 | −4,00 | −6,00 | −5,00 | 6,00 | 23,00 | −2,00 | −0,16 | −0,48 | −1,68 | −1,68 |
| −12,00 | −10,00 | −7,00 | −13,00 | −16,00 | −18,00 | −21,00 | −24,00 | −23,00 | −15,00 | −2,00 | −31,00 | −24,00 | −23,00 | −15,00 | −3,00 |
| – | – | – | – | – | −600,00 | −420,00 | −800,00 | −460,00 | −55,56 | −3,28 | −124,00 | −1200,00 | −383,33 | −71,43 | −14,29 |
| −13,00 | −12,00 | −9,00 | −15,00 | −16,00 | −18,00 | −21,00 | −24,00 | −24,00 | −17,00 | −2,00 | −32,00 | −98,00 | −24,00 | −15,00 | −8,00 |
| – | −7,69 | −25,00 | 66,67 | 6,67 | 12,50 | 16,67 | 14,29 | – | −29,17 | −88,24 | 1500,00 | 206,25 | −75,51 | −37,50 | −46,67 |
| 17,07 | – | – | – | – | – | – | 0,02 | 0,10 | 0,45 | 16,85 | 17,07 | 17,07 | 17,07 | 17,07 | 17,07 |
Podrobnosti
Ključne številke izkaza poslovnega izida
ⓘPrihodki in rast prihodkov
Prihodki so izhodišče vsakega izkaza poslovnega izida — merijo skupne prodaje, ki jih Biocept ustvari iz svoje osnovne dejavnosti. Rast prihodkov (izražena kot sprememba v odstotkih od leta do leta) je eden od najpomembnejših kazalnikov poslovnega zagona. Trajnostna rast nad 10 % letno se šteje za močno, medtem ko padajoči prihodki predstavljajo resno opozorilo, ki zahteva preiskavo.
Bruto marža
Bruto marža = (Prihodki − Stroški prodanih blaga) ÷ Prihodki. Razkriva, kolikšen odstotek vsakega dolarja prihodkov Biocept zadrži po neposrednih proizvodnih stroških. Visoke bruto marže (nad 50 %) so značilne za poslovanja z majhno količino sredstev, kot so programska oprema in blagovne znamke, medtem ko kapitalno intenzivne industrije, kot je proizvodnja, pogosto delujejo z manj kot 30 %. Primerjajte bruto marzho Biocept s konkurenti v industriji in jo spremljajte skozi čas, da ugotovite izboljšano ali poslabšano cenovno moč.
EBIT in marža EBIT
EBIT meri operativni dobiček — tisto, kar ostane po odbitku vseh operativnih stroškov (vključno s stroški R&R, prodaje in administracije) od bruto dobička. Marža EBIT to prikaže kot odstotek prihodkov. Ker izključuje obresti in davke, EBIT omogoča poštene primerjave med podjetji z različnimi ravnmi dolga in davčnimi pristojnosti. Naraščajoča marža EBIT kaže na izboljšano operativno učinkovitost.
Neto dohodek in dobiček na delnico (EPS)
Neto dohodek je končni dobiček podjetja po vseh stroških, obrestih in davkih. Deljenje neto dohodka s številom Outstanding delnic vam daje EPS — en sam najbolj vpliven metriko pri vrednotenju delnic. Dosledna rast EPS je glavni pogon dolgoročnega rasta cene delnice. Vedno preverite, ali rast EPS izvira iz resničnega izboljšanja dobička ali iz odkupa delnic, ki zmanjšuje število delnic.
Izdane delnice
Skupno število delnic, ki jih je Biocept izdal. Padajoče število delnic (preko odkupa) dviguje EPS in signalizira zaupanje managementa. Naraščajoče število delnic (preko izdaje delnic) razvodnjuje obstoječe lastnike. Vedno spremljajte to število skupaj z EPS, da dobite celovito sliko ustvarjanja vrednosti na delnico.
Ocene analitikov
Projicirane številke predstavljajo soglasne ocene strokovnih analitikov. Primerjajte te napovedi z zgodovinskim stopnjami rasti Biocept, da ocenite, ali so pričakovanja realistična. Podjetje, ki dosledno presega soglasne ocene, ima svoje delnice nagrajene skozi čas, medtem ko se ponovljeni zamiki bremenijo zaupanja vlagateljev.
Biocept robni dobički delnice
3 leta
5 let
10 let
25 let
Največ
Details
Biocept Prihodek na delnico, EBIT, Dobiček na delnico
3 leta
5 let
10 let
25 let
Največ
Details
Biocept poslovni model in analiza delnice
Biocept Employees
3 leta
5 let
10 let
25 let
Največ
Details
Biocept Segmenti
Biocept Prihodki po segmentu (1/3)
3 leta
Največ
Details
Biocept Prihodki po segmentu (2/3)
3 leta
5 let
Največ
Details
Biocept Prihodki po segmentu (3/3)
3 leta
5 let
Največ
Details
Biocept Prihodki po regiji
3 leta
5 let
10 let
Največ
Details
Biocept vrednotenje po pošteni vrednosti
Podrobnosti
Ocena poštene vrednosti
ⓘKaj je poštena vrednost?
Poštena vrednost je ocena prave "vrednosti" delnice na podlagi njenih finančnih temeljnih podatkov, neodvisno od trenutne tržne cene. Če je izračunana poštena vrednost višja od trenutne cene delnice, je delnica lahko podocenjena — in obratno. Ta grafikon prikazuje tri različne pristope poštene vrednosti, tako da jih lahko medsebojno primerjate.
Poštena vrednost na podlagi dobitka
Izračuna se z množenjem trenutnega dobitka na delnico (EPS) s povprečnim zgodovinskim razmerjem cena/dobiček v izbranem večletnem obdobju. Glajenje v več letih odpravlja začasne konice ali padce. Če ta poštena vrednost presega tržno ceno, to nakazuje, da je delnica poceni v primerjavi z njeno sposobnostjo ustvarjanja dobička.
Primer: Poštena vrednost (dobiček) 2022 = EPS 2022 × Povprečno razmerje KGV 2019–2021
Poštena vrednost na podlagi prihodka
Izpeljana z množenjem prihodka na delnico s povprečnim zgodovinskim razmerjem cena/prodaja. Ta metoda je posebej uporabna za podjetja s spremenljivim ali začasno zmanjšanim dobitkom, saj je prihodek ponavadi bolj stabilen kot dobiček. Odgovarja: "Po kakšni ceni je trg v preteklosti vrednoval vsak dolar prodaje tega podjetja?"
Primer: Poštena vrednost (prihodek) 2022 = Prihodek na delnico 2022 × Povprečno razmerje KUV 2019–2021
Poštena vrednost na podlagi dividende
Izračuna se z deljenjem dividende na delnico s povprečno zgodovinsko donosnostjo dividend. Ta pristop je najbolj relevantan za zrela, dosledno dividende izplačujoča podjetja. Če je dobljena poštena vrednost višja od trenutne cene, to pomeni, da delnica ponuja boljšo donosnost kot njeno zgodovinsko povprečje.
Primer: Poštena vrednost (dividenda) 2022 = Dividenda na delnico 2022 ÷ Povprečna donosnost 2019–2021
Kako uporabljati ta grafikon
Kadar se vse tri črte poštene vrednosti zbližajo nad trenutno ceno, je to okrepitev primera, da je delnica podocenjena. Kadar se razhajajo, preiskati, zakaj — morda gre za strukturni premik v robnih dobičkih, politiki izplačil ali stopnji rasti. Napredne ocene na desni razširijo analizo z uporabo napovedanih temeljnih podatkov, kar vam pomaga oceniti, ali trenutna cena že odraža pričakovanja prihodnje rasti.
Biocept vrednotenje po zgodovinskem razmerju cena-dobiček, večkrtniku EBIT in razmerju cena-prihodki
Biocept letna donosnost
Podrobnosti
Letna donosnost
ⓘKaj prikazuje ta grafikon
Ta grafikon razdeli skupno letno donosnost v dve komponenti: donosnost cene (dobički ali izgube iz gibanja cene delnice) in donosnost dividende (dohodek prejeto od izplačil dividend). Skupaj predstavljajo skupno donosnost, ki bi jo je vlagatelj zaslužil v vsakem koledarskem letu.
Donosnost cene
Donosnost cene meri odstotnino spremembe cene delnice od 1. januarja do 31. decembra vsakega leta. Pozitivne črte nakazujejo, da se je delnica podražila; negativne črte kažejo padec. To je komponenta, na katero se večina vlagateljev osredotoča, vendar le delno pripoveduje zgodbo — posebej za delnice, ki izplačujejo dividende.
Donosnost dividende
Donosnost dividende predstavlja dohodek, ustvarjen z dividendami, izplačanimi v letu, izraženo kot odstotek začetne cene delnice. Čeprav se lahko zdi majhna v kateremkoli letu (navadno 1–4 % za uveljavljenih podjetij), se dividende sčasoma sestavljajo in so zgodovinsko prispevale približno 40 % skupne donosnosti borznega trga.
Kaj poiskati
Preglejte, koliko let je bilo pozitivnih nasproti negativnim donosnostim, da bi ocenili doslednost. Delnica, ki ima večino let s pozitivnimi rezultati in majhnimi upadi, nakazuje manjše tveganje. Primerjajte tudi letno donosnost s primerjalnim indeksom — dosledna preseganja trga je značilnost močne naložbe. Obratite pozornost na najslabša leta: razumevanje tveganja padca je enako pomembno kot lovljenje potenciala rasti.
Biocept izdane delnice
3 leta
5 let
10 let
25 let
Največ
Details
Biocept Delitve delnic
Trenutne Biocept napovedi in ciljne cene v Avgust 2026
Cenovna tarča analitikov 2026Biocept Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 14. 4. 2023 | Downgrade | BuyHold | – | |
| 25. 11. 2020 | Upgrade | HoldBuy | – | |
| 25. 11. 2020 | Maintained | Buy | 71 | |
| 10. 11. 2016 | Upgrade | HoldBuy | – | |
| 31. 1. 2013 | Downgrade | BuyHold | 71 | |
| 18. 10. 2012 | Maintained | Buy | 71 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Biocept Ocene dobička in presenečenja
| Datum | Ocena EPS | Dejanski EPS | Ocena prihodkov | Odziv delnice | Četrtletno poročilo |
|---|---|---|---|---|---|
| 29. 3. 2023 | −0,23USD | - | 5,58 Mio.USD | - | 2022 Q4 |
| 29. 11. 2022 | −0,20USD | - | 9,67 Mio.USD | - | 2022 Q3 |
| 10. 11. 2022 | −0,16USD | - | 12,66 Mio.USD | - | 2022 Q2 |
| 23. 5. 2022 | −0,14USD | - | 11,66 Mio.USD | - | 2022 Q1 |
| 5. 4. 2022 | −0,19USD | - | 11,27 Mio.USD | - | 2021 Q4 |
| 15. 11. 2021 | 0,07USD | - | 16,31 Mio.USD | - | 2021 Q3 |
| 16. 8. 2021 | −0,16USD | - | 9,89 Mio.USD | - | 2021 Q2 |
| 29. 3. 2021 | −0,28USD | - | 12,51 Mio.USD | - | 2020 Q4 |
| 12. 11. 2020 | −0,48USD | - | 2,54 Mio.USD | - | 2020 Q3 |
| 12. 8. 2020 | −0,51USD | - | 1,32 Mio.USD | - | 2020 Q2 |
Struktura lastnikov delnic Biocept
| % | Ime |
|---|---|
0,76105% | |
0,25235% | |
0,13235% | |
0,03031% | |
0,02959% | |
0,00152% |
Biocept Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
44,10% | SEC ↗ | |
12,00% | SEC ↗ | |
12,00% | SEC ↗ | |
12,00% | SEC ↗ | |
9,99% | SEC ↗ | |
9,99% | SEC ↗ | |
9,99% | SEC ↗ | |
9,99% | SEC ↗ | |
9,99% | SEC ↗ | |
9,90% | SEC ↗ |
Biocept Supply Chain
Biocept Dobavna veriga
Korelacija: kako tesno se gibljejo cene delnic skupaj
| # | Ime | Trend | |||
|---|---|---|---|---|---|
| 1 | Kadmon Holdings, Inc. | −0,89 | −0,84 | — | |
| 2 | −0,63 | −0,81 | −0,80 | ||
| 3 | 0,85 | −0,12 | −0,67 | ||
| 4 | 0,91 | 0,54 | −0,64 | ||
| 5 | 0,83 | 0,44 | −0,63 |
Pogosto postavljena vprašanja o delnici Biocept
Biocept Inc. operates as a molecular diagnostics company. Its business model revolves around developing and commercializing proprietary circulating tumor cell and circulating tumor DNA assays to provide physicians with insights for treating and monitoring cancer patients. By utilizing patented technologies, Biocept's liquid biopsy tests detect and analyze tumor-associated biomarkers from a simple blood sample. This enables healthcare providers to make informed decisions regarding the selection of targeted therapies, monitoring treatment response, and detecting the development of resistance mutations in cancer patients. Biocept aims to improve patient outcomes and contribute to advancing precision medicine in oncology.
Biocept Inc is primarily active in the healthcare and biotechnology industries. As a leading molecular diagnostics company, Biocept specializes in providing clinically actionable information to healthcare providers, assisting in the treatment of patients with cancer. Through its proprietary liquid biopsy technology, Biocept enables the detection and monitoring of circulating tumor cells and circulating tumor DNA, aiding in the diagnosis and management of various types of cancer. With its innovative solutions and commitment to advancing personalized medicine, Biocept continues to make significant contributions to the healthcare industry.
The main competitors of Biocept Inc in the market are companies like Guardant Health, Inc. and Genomic Health, Inc. These companies also provide molecular diagnostic testing services and solutions for cancer detection and treatment. However, what sets Biocept apart is its unique liquid biopsy technology and its ability to capture and analyze tumor cells from a simple blood sample. With its innovative and efficient testing methods, Biocept Inc remains at the forefront of the market, offering reliable and accurate diagnostic solutions to patients and healthcare providers.
Biocept Inc is a leading molecular diagnostics company that specializes in providing liquid biopsy tests for cancer detection and monitoring. The company was founded in 1997 and is headquartered in San Diego, California. Biocept utilizes proprietary technology to analyze circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) present in a patient's blood sample. These tests aid in early cancer detection, treatment selection, and monitoring of therapeutic effectiveness. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to advance personalized medicine and enhance patient care. Biocept Inc has gained recognition for its innovative solutions and continues to make significant contributions in the field of molecular diagnostics.
Biocept Inc has achieved significant milestones in its history. Some notable achievements of the company include the successful launch of their liquid biopsy platform, which enables the detection and monitoring of cancer through blood samples. They have also secured multiple patents related to their proprietary technology. Biocept Inc has established partnerships with renowned healthcare institutions and laboratories, further expanding their reach and impact. Additionally, the company has announced successful collaborations with pharmaceutical companies to develop precision medicine strategies. These milestones highlight Biocept Inc's commitment to innovation, research, and improving cancer diagnosis and treatment.
Biocept Inc is primarily present in the United States. As a leading molecular diagnostics company, Biocept focuses on providing advanced oncology testing services to physicians and patients nationwide. With their state-of-the-art laboratory facilities and cutting-edge technology, Biocept offers innovative liquid biopsy tests that detect and monitor various cancer biomarkers. By leveraging their expertise in circulating tumor cells and circulating tumor DNA analysis, Biocept aims to enhance cancer detection and treatment strategies, ultimately improving patient outcomes.
Biocept Inc represents values of innovation, quality, and commitment to improving patient care. With a corporate philosophy focused on leveraging advanced diagnostics, Biocept aims to enable oncologists to make more informed treatment decisions. By developing and commercializing proprietary liquid biopsy tests, the company helps provide actionable biomarker information for personalized medicine. Biocept embraces cutting-edge technologies, rigorous research practices, and strategic collaborations to deliver reliable and accurate results. Through their dedication to accuracy, speed, and accessibility, Biocept is streamlining the diagnosis and monitoring of cancer, ultimately facilitating better patient outcomes.
6 analysts currently rate the Biocept stock: 0 recommend buying, 3 holding and 3 selling.
Biocept Inc specializes in the development and marketing of liquid biopsy technologies and products for cancer diagnostics. The company's business model involves generating higher income and increasing profits through the sale of diagnostic tests and services for cancer medicine. Biocept Inc offers a wide range of diagnostic tests for cancer patients aimed at early detection and more accurate classification of the disease. These products range from Helix for breast and lung cancer to Pathnostics for prostate cancer, as well as a variety of tests for rare cancer types. These diagnostic tests use advanced technologies like liquid biopsy to provide patients with precise and comprehensive information about their cancer. The company has developed its technology to be able to isolate cancer cells from a small amount of blood, providing an accurate and non-invasive method for cancer diagnosis that spares patients from undergoing a biopsy. This technology allows doctors to tailor treatment more precisely and monitor the progression of the disease in an accurate manner. In addition to products, Biocept Inc also provides services for cancer patients. The company has a team of experienced medical professionals who perform the diagnostic tests and interpret the results. The results of these tests are an important basis for making decisions about the patient's further treatment. The company's focus is on delivering high-quality diagnosis to ensure the best possible care for each individual patient. In the field of medical diagnostics, Biocept Inc has established a strong competitive position. Through continuous development of its products and services, the company has built a reputation for innovative and reliable diagnostic tests in the market. The company also leverages partnerships with other companies in the healthcare industry to expand its business and introduce new products and services to the market. With its advanced technologies and high standardization measures, Biocept Inc is well positioned for collaboration with other companies. These partnerships enable faster product launches and better integration of the partners' products and services. Overall, Biocept Inc's business model is focused on generating higher income and increasing profits through the development and marketing of liquid biopsy technologies and products for cancer diagnostics. The company strives to continuously improve its products and services and introduce new partnerships to thrive in a competitive environment.
Prihodkov za Biocept trenutno ni mogoče izračunati.
Dobička za Biocept trenutno ni mogoče izračunati.
Razmerja cena-dobiček za Biocept trenutno ni mogoče izračunati.
Razmerja cena-prihodki za Biocept trenutno ni mogoče izračunati.
Eulerpool ocena kvalitete za Biocept je 4/10.
ISIN Biocept je US09072V5012. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.
WKN Biocept je A2QEQE. WKN (Wertpapierkennnummer) je šestmestna nemška oznaka za identifikacijo vrednostnih papirjev.
Ticker Biocept je BIOC. Ticker simbol se uporablja za trgovanje z delnicami Biocept na borzi.
Biocept je uvrščena v sektor 'Zdravstvo'.
Dividende Biocept so izplačane v USD.
Biocept delnica
Biocept Konkurenčna skupina
Vse ključne kazalnike in poglobljeno analizo Biocept v detaljnem pregledu
Naša analiza delnic Biocept vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (P/E), razmerje cena/prihodki (P/S), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Biocept. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: